Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada
Links shared publicly online about this topic.
- 1,680total visits
Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada
Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.
View full resource at news-medical.net
Tags: Diabetes, Stroke, Thrombotic Event, Merck & Co., News
Most Recently Shared on October 13, 2009 at 1:06 pm By:
Stroke News: Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada: Merck Frosst Ca.. http://twurl.nl/etxsgv
Advertisement
